Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a Study of ANA773 Tosylate Plus Ribavirin in Chronic Hepatitis C Virus Infection
2011-000728-14Phase 2Terminated
- Sponsor
- Anadys Pharmaceuticals
- Start
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of RG-7795 in chronic hepatitis C (CHC), sponsored by Anadys Pharmaceuticals. Primary endpoints: Safety and tolerability of ANA773 tosylate with ribavirin, Pharmacodynamic effects of ANA773 tosylate with ribavirin and 1 more. Started May 2011; status: terminated.
02
Drugs
RG-7795
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2011-000728-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000728-14.